Aronex Pharmaceuticals Announces Expiration of Warrants
THE WOODLANDS, Texas, June 12 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX - news) today
announced the expiration of the majority of the warrants that remained outstanding from the Company's issuance of
warrants in connection with the Company's September 1995 merger with Oncologix, Inc. The now-expired warrants
had been exercisable for an aggregate of approximately 3,034,000 shares of the Company's common stock. The
Company has 15,467,281 shares issued and outstanding and options and warrants outstanding exercisable for
approximately 3,197,000 shares.
Aronex Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes proprietary innovative
medicines to treat cancer and infectious diseases. Aronex Pharmaceuticals currently has four products in clinical
development, two of which are in an advanced stage, as well as a pipeline of additional products.
Any statements which are not historical facts contained in this release are forward looking statements that involve risks
and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect
of economic conditions, intellectual property rights and litigation, clinical trials, governmental regulation, competitive
products, risks in product and technology development, the results of financing efforts, the ability to complete
transactions and other risks identified in the Company's Securities and Exchange Commission filings.
SOURCE: Aronex Pharmaceuticals, Inc. |
